Paul M. Rivard comments on Supreme Court arguments in Helsinn v. Teva in World IP Review

Paul M. Rivard discusses the potential for Supreme Court justices to focus more on the text of the patent statute than its historical context during arguments in Helsinn Healthcare v. Teva Pharmaceuticals, and how that may influence their decision, in World Intellectual Property Review.

Click here to read the article, “SCOTUS likely to reverse Helsinn v Teva ruling, say lawyers.”

Posted: December 4, 2018

Contact Banner Witcoff Share on LinkedIn View this page as a pdf Share on Twitter Email this page Print this page